KCNQ4

Potassium voltage-gated channel subfamily KQT member 4 · P56696 · KCNQ4 on Sugi Atlas →

7,064 patent compounds predicted against KCNQ4, 3,156 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Flupirtine (SCHEMBL505322)	0.58	7/20
Flupirtine (SCHEMBL505880)	0.54	7/20
SCHEMBL4981642	0.52	7/20
Flupirtine (SCHEMBL505354)	0.51	7/20
Ezogabine (SCHEMBL20835)	1.00	6/20
Ezogabine (SCHEMBL4054750)	1.00	6/20
Ezogabine (SCHEMBL154715)	0.98	6/20
Ezogabine (SCHEMBL155918)	0.98	6/20
SCHEMBL3102203	0.87	6/20
SCHEMBL1226516	0.80	6/20
SCHEMBL3098428	0.71	6/20
Flupirtine (SCHEMBL25009)	0.65	6/20
Flupirtine (SCHEMBL3896230)	0.65	6/20
Flupirtine (SCHEMBL505535)	0.64	6/20
Flupirtine (SCHEMBL505847)	0.64	6/20
Flupirtine (SCHEMBL505446)	0.63	6/20
Flupirtine (SCHEMBL505680)	0.63	6/20
Flupirtine (SCHEMBL1649863)	0.63	6/20
Flupirtine (SCHEMBL505608)	0.62	6/20
Flupirtine (SCHEMBL505911)	0.62	6/20

Clinical trials — most relevant to KCNQ4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Study to Treat Major Depressive Disorder With a New Medication	PHASE2	COMPLETED
Long QT Syndrome Screening in Newborns	PHASE2	UNKNOWN
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
A Study of JMT203 in Patients With Cancer Cachexia	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Prospective Identification of Long QT Syndrome in Fetal Life	nan	COMPLETED
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KCNQ4 binder may also engage these)

Protein	Name	Similarity
Q9JK97	—	1.000	Q9JK97 →
Q9JK96	—	1.000	Q9JK96 →
KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	0.999	landscape →
Q9TTJ7	—	0.998	Q9TTJ7 →
Q9Z351	—	0.997	Q9Z351 →
O97531	—	0.997	O97531 →
O88943	—	0.997	O88943 →
O88944	—	0.995	O88944 →
Q8K3F6	—	0.995	Q8K3F6 →
P58126	—	0.994	P58126 →
P97414	—	0.993	P97414 →
Q9MYS6	—	0.993	Q9MYS6 →
O70344	—	0.992	O70344 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	0.992	landscape →
Q9Z0N7	—	0.991	Q9Z0N7 →
KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	0.990	landscape →
KCNQ3	Potassium voltage-gated channel subfamily KQT member 3	0.990	landscape →
Q9TUI4	—	0.987	Q9TUI4 →
Q9R1T9	—	0.986	Q9R1T9 →
P15389	—	0.986	P15389 →
Q9JK45	—	0.986	Q9JK45 →
Q60603	—	0.985	Q60603 →
SCN5A	Sodium channel protein type 5 subunit alpha	0.985	landscape →
KCNH3	Voltage-gated inwardly rectifying potassium channel KCNH3	0.984	landscape →
Q63099	—	0.984	Q63099 →
O89047	—	0.984	O89047 →
A6H8H5	—	0.983	A6H8H5 →
Q03717	—	0.983	Q03717 →
Q9UQ05	—	0.983	Q9UQ05 →
Q9JJV9	—	0.983	Q9JJV9 →